TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10099127

Group type: EXPERIMENTAL
Intervention: Vaginal immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal immunization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral immunization
Number of subjects: 0
Study: 8746604

Group type: EXPERIMENTAL
Intervention: cilazapril 5 mg once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg once a day
Number of subjects: 40
Study: 2036929

Group type: EXPERIMENTAL
Intervention: Double stapling technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single stapling technique
Number of subjects: 70
Study: 7149897

Group type: EXPERIMENTAL
Intervention: Social skills training alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Social skills training combined with cognitive modification
Number of subjects: 22

Group type: COMPARATOR
Intervention: Social skills training (both conditions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated targets
Number of subjects: 22
Study: 31215430

Group type: EXPERIMENTAL
Intervention: Long-menu format
Number of subjects: 88

Group type: COMPARATOR
Intervention: Type A format
Number of subjects: 88
Study: 28802288

Group type: EXPERIMENTAL
Intervention: Pectin-supplemented enteral nutrition (PEC/EN)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 125
Study: 25820146

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) iv (500 UI/kg, repeated at 24 and 48 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Methylprednisolone (MP) according to the NASCIS III protocol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) and Methylprednisolone (MP)
Number of subjects: 19
Study: 23671895

Group type: EXPERIMENTAL
Intervention: Amitriptyline 10mg daily
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amitriptyline 10mg daily with Pindolol 5mg twice daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surrogate placebo (Loratadine 10mg daily)
Number of subjects: 62
Study: 21489084

Group type: EXPERIMENTAL
Intervention: Insulin analogues (various regimens: basal, prandial, biphasic, basal-bolus)
Number of subjects: 38803

Group type: EXPERIMENTAL
Intervention: Insulin analogues (basal-bolus regimen)
Number of subjects: 38803

Group type: EXPERIMENTAL
Intervention: Insulin analogues (overall analysis)
Number of subjects: 38803
Study: 19719960

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (niacin ER) and atorvastatin
Number of subjects: 108
Study: 17353873

Group type: EXPERIMENTAL
Intervention: Testosterone administered as transdermal gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New compounds targeting androgen receptors
Number of subjects: 0
Study: 14735339

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (small mesh)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lichtenstein hernioplasty
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 123
Study: 10383560

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray (0.9 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 0
Study: 8712384

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 28
Study: 1924023

Group type: EXPERIMENTAL
Intervention: 100 mg of caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20
Study: 6580491

Group type: EXPERIMENTAL
Intervention: Polychemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 334

Group type: COMPARATOR
Intervention: No polychemotherapy for relapse
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Overall group (all patients)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Polychemotherapy after relapse
Number of subjects: 334

Group type: COMPARATOR
Intervention: No polychemotherapy after relapse
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Polychemotherapy group
Number of subjects: 334

Group type: COMPARATOR
Intervention: No-relapse group
Number of subjects: 334

Group type: COMPARATOR
Intervention: No polychemotherapy after relapse group
Number of subjects: 334
Study: 31984735

Group type: EXPERIMENTAL
Intervention: HCD containing 9.5% CO (COH)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HCD containing 4.75% CO (COL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HCD
Number of subjects: 32

Group type: COMPARATOR
Intervention: NCD
Number of subjects: 32
Study: 30785406

Group type: EXPERIMENTAL
Intervention: Mobile phone-based eHealth program (EH)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care treatment (UC)
Number of subjects: 168
Study: 29428373

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2 for 6 cycles)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sequential chemotherapy (paclitaxel for 3 cycles followed by cisplatin for 3 cycles)
Number of subjects: 46
Study: 26325671

Group type: EXPERIMENTAL
Intervention: 2014 ISUP grading (grades 1-5)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: 2014 ISUP grading
Number of subjects: 496

Group type: COMPARATOR
Intervention: 2005 modified Gleason system (MGS)
Number of subjects: 496
Study: 23109623

Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal (CoM) total hip replacement
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metal-on-metal (MoM) total hip replacement
Number of subjects: 83
Study: 20531348

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 18840821

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study: 16055461

Group type: EXPERIMENTAL
Intervention: 400 microg conventional misoprostol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 400 microg SR misoprostol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 800 microg SR misoprostol
Number of subjects: 31
Study: 12074329

Group type: EXPERIMENTAL
Intervention: FHIG (infusional fluorouracil 2.6 g/m2 over 24 hours once per week for 6 weeks, infusional hydroxyurea 4.3 g/m2 over 24 hours once per week for 6 weeks, interferon-alpha-2a 9 MU subcutaneously three times per week for 6 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: AD (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 intravenously every 21 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Quality of life assessment for FHIG
Number of subjects: 29
Study: 10329290

Group type: EXPERIMENTAL
Intervention: Stimulus speed of 4 degrees/s in V5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus speed of 8 degrees/s in V5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus speed of 4 to 16 degrees/s in V3a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast vs slow speed and color > luminance contrast in V5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving vs stationary motion and color > luminance contrast in V4
Number of subjects: 0
Study: 8961505

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (20-40 micrograms, injected at the same site as the vaccine)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 108
Study: 1849343

Group type: EXPERIMENTAL
Intervention: Nurse practitioner post-visit support
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual follow-up advice
Number of subjects: 190
Study: 6340275

Group type: EXPERIMENTAL
Intervention: Cyclosporine alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Methotrexate and amphotericin B
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cyclosporine plus amphotericin B
Number of subjects: 47
Study: 29696357

Group type: EXPERIMENTAL
Intervention: Post-acute assessment (8 weeks after first in-patient treatment)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1-year follow-up assessment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multiple regression models
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Factors associated with higher stigma experiences
Number of subjects: 72
Study: 29735878

Group type: EXPERIMENTAL
Intervention: Health mentoring program
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 26960799

Group type: EXPERIMENTAL
Intervention: Third‐ and fourth‐degree anal sphincter tears
Number of subjects: 558

Group type: COMPARATOR
Intervention: Normal vaginal deliveries (comparison group)
Number of subjects: 558
Study: 24268872

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure control (study group, n=20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 43
Study: 22701555

Group type: EXPERIMENTAL
Intervention: Adherence to ART (defined as taking 100% of prescribed doses and not interrupting treatment for more than two consecutive days)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Inconsistent condom use (ICU)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Adherence to ART
Number of subjects: 459
Study: 20402305

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Monopolar electrocauter
Number of subjects: 61
Study: 17556408

Group type: EXPERIMENTAL
Intervention: TAK-044 (100 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: TAK-044 (750 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 18318098

Group type: EXPERIMENTAL
Intervention: Evidence-based health care approach in orthodontics
Number of subjects: 0
Study: 14736774

Group type: EXPERIMENTAL
Intervention: Fixed combination of latanoprost 0.005% and timolol 0.5% (once daily morning dose)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Unfixed combination of latanoprost 0.005% (once daily evening) and timolol 0.5% (twice daily)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Comparison of fixed and unfixed combinations
Number of subjects: 190
Study: 10837880

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 108

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fluoxetine, Sertraline, Paroxetine
Number of subjects: 108
Study: 9394641

Group type: EXPERIMENTAL
Intervention: Power grasp
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Smooth-rim handwheel in frontal plane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Counterclockwise torque exertion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MVTE for women
Number of subjects: 40
Study: 1388702

Group type: EXPERIMENTAL
Intervention: Amantadine (0.2 g amantadine‐sulfate in 500 ml NaCl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (500 ml NaCl)
Number of subjects: 20
Study: 3911877

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 864

Group type: COMPARATOR
Intervention: Cefotaxime, Cefoperazone
Number of subjects: 864
Study: 31013233

Group type: COMPARATOR
Intervention: Passive strategy consisting of preventive information
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Passive strategy combined with an active component of case management (MAC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Passive strategy, case management and a psychoeducational programme (PSyMAC)
Number of subjects: 163
Study: 29798502

Group type: EXPERIMENTAL
Intervention: Manual reduction combined with psychological intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simple manipulation (Control group)
Number of subjects: 68
Study: 26485501

Group type: EXPERIMENTAL
Intervention: Complete device removal and antibiotic treatment for six weeks
Number of subjects: 71
Study: 24561009

Group type: EXPERIMENTAL
Intervention: CXR-defined apical LV lead position
Number of subjects: 447

Group type: COMPARATOR
Intervention: MD-determined anterior or apical LV lead position
Number of subjects: 447

Group type: COMPARATOR
Intervention: CXR-determined anterior LV lead position
Number of subjects: 447
Study: 22760902

Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interval exercise training
Number of subjects: 37
Study: 21174567

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study: 17667128

Group type: EXPERIMENTAL
Intervention: Continuous direct anodal microcurrent applied to silver nylon wound contact dressings
Number of subjects: 30
Study: 15701763

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (n = 43) for 6 months followed by 6-month usual-care observation period
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care (n = 34) for 6 months followed by 6-month usual-care observation period
Number of subjects: 77
Study: 11942883

Group type: EXPERIMENTAL
Intervention: Nifedipine (8 mg sublingually)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Hydralazine (5-10 mg intravenous)
Number of subjects: 126
Study: 9869161

Group type: COMPARATOR
Intervention: FIX‐SD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: FIX‐SD‐15
Number of subjects: 11

Group type: COMPARATOR
Intervention: FIX‐SD and FIX‐SD‐15
Number of subjects: 11

Group type: COMPARATOR
Intervention: FIX
Number of subjects: 11
Study: 8731830

Group type: EXPERIMENTAL
Intervention: Sulperazone
Number of subjects: 207

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 207
Study: 2749951

Group type: EXPERIMENTAL
Intervention: Mixed-beam (neutron/photon) radiotherapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional photon (x-ray) radiotherapy
Number of subjects: 91
Study: 132705

Group type: EXPERIMENTAL
Intervention: Topical tetracycline preparation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oral tetracycline 0.5 gm daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 31521872

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 1647
Study: 29920177

Group type: EXPERIMENTAL
Intervention: Telephone-supported ergonomic education (1 face-to-face session + 3 weekly telephone sessions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard face-to-face ergonomic education (1 session)
Number of subjects: 110
Study: 28073039

Group type: EXPERIMENTAL
Intervention: Sleep disturbances evaluated using the Leeds Sleep Evaluation Questionnaire (LSEQ) within 2 weeks after ACS.
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Sleep disturbances (LSEQ)
Number of subjects: 828
Study: 27087103

Group type: EXPERIMENTAL
Intervention: Usual care plus DMTAC
Number of subjects: 76
Study: 24101036

Group type: EXPERIMENTAL
Intervention: Internet-based aftercare intervention
Number of subjects: 334

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 334
Study: 22389047

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarette
Number of subjects: 22

Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 22
Study: 19631853

Group type: EXPERIMENTAL
Intervention: Direct pulp capping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17449917

Group type: EXPERIMENTAL
Intervention: High-pressure parallel waterjet (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pulse lavage (n = 9)
Number of subjects: 21
Study: 15696244

Group type: EXPERIMENTAL
Intervention: Edifoligide (E2F Decoy) administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation.
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 1400
Study: 12653822

Group type: EXPERIMENTAL
Intervention: exercise counselling
Number of subjects: 299

Group type: COMPARATOR
Intervention: health education advice
Number of subjects: 299
Study: 10547465

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus radiation
Number of subjects: 0
Study: 8739854

Group type: EXPERIMENTAL
Intervention: Cancer patients with solid tumors
Number of subjects: 975

Group type: COMPARATOR
Intervention: Non-cancer subjects
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Cancer patients with upper gastrointestinal tract tumors
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Cancer patients subdivided according to the extension of the tumor (TNM system)
Number of subjects: 975
Study: 1764147

Group type: EXPERIMENTAL
Intervention: 24-hour, in-hospital telephone line for advice by postpartum nurses
Number of subjects: 260

Group type: COMPARATOR
Intervention: Regular ward telephones (control group)
Number of subjects: 260
Study: 7048172

Group type: EXPERIMENTAL
Intervention: chemo + radiotherapy + BCG therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: chemo + radiotherapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BCG therapy
Number of subjects: 16
Study: 31596491

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target < 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target < 140 mm Hg)
Number of subjects: 9361
Study: 28546012

Group type: EXPERIMENTAL
Intervention: Tramadol 1mg.kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clonidine 1mcg.kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5mcg.kg‐1
Number of subjects: 90
Study: 26808841

Group type: EXPERIMENTAL
Intervention: Isometric squats at 140° knee angle
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isometric squats at 90° knee angle
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isometric squats at 90° for high jumpers
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isometric squats at 140° for high jumpers
Number of subjects: 14
Study: 24637999

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (C2 to C22)
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (C2 to C6) plus placebo (C7 to C22)
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo (C2 to C22)
Number of subjects: 1759
Study: 22289280

Group type: EXPERIMENTAL
Intervention: Tai Chi training plus usual care (UC)
Number of subjects: 86
Study: 20919771

Group type: EXPERIMENTAL
Intervention: Risk‐Taking and Self‐Harm Inventory for Adolescents (RTSHIA)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Standardized measures of adolescent psychopathology
Number of subjects: 722
Study: 17627173

Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam FDDF sublingual tablets
Number of subjects: 80

Group type: COMPARATOR
Intervention: IM injection of 40 mg piroxicam
Number of subjects: 80
Study: 15850682

Group type: EXPERIMENTAL
Intervention: Flap group (12 children)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vertical group (7 children)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 24
Study: 12039932

Group type: EXPERIMENTAL
Intervention: Consultation Planning
Number of subjects: 94

Group type: COMPARATOR
Intervention: Productive Listening (Control)
Number of subjects: 94
Study: 9594288

Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly at 3, 2, and 1 month before delivery)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: HBIG
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control
Number of subjects: 204
Study: 7959520

Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐40 mg, n = 54)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fluoxetine (20‐60 mg, n = 52)
Number of subjects: 106
Study: 3298327

Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30782722

Group type: EXPERIMENTAL
Intervention: Problem Areas In Diabetes (PAID) scale intervention in clinical diabetes consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical diabetes consultations without the PAID scale
Number of subjects: 0
Study: 29351604

Group type: EXPERIMENTAL
Intervention: Results-based financing (RBF)
Number of subjects: 0
Study: 27483065

Group type: EXPERIMENTAL
Intervention: Vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n=101)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vasopressin and placebo (n=104)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Norepinephrine and hydrocortisone (n=101)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Norepinephrine and placebo (n=103)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 409

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 409
Study: 24501378

Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity aerobic exercise intervention (45 minutes/day, 5 days/week)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity aerobic exercise intervention
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control
Number of subjects: 173
Study: 22220766

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg followed by 250 mg 24 hours later
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (healthy sextants)
Number of subjects: 9
Study: 19170197

Group type: EXPERIMENTAL
Intervention: Aripiprazole (AP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tetrabenazine (TBZ)
Number of subjects: 6
Study: 17141356

Group type: EXPERIMENTAL
Intervention: OSWALD under informative dropout (ID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bootstrap procedure supplementing OSWALD
Number of subjects: 0

Group type: COMPARATOR
Intervention: OSWALD under completely random dropout (CRD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OSWALD under random dropout (RD)
Number of subjects: 0
Study: 15040643

Group type: EXPERIMENTAL
Intervention: Zidovudine 600 mg once/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Zidovudine 300 mg twice/day
Number of subjects: 32
Study: 11139305

Group type: EXPERIMENTAL
Intervention: Videotape information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written information
Number of subjects: 0